eClinicalWorks vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Major ambulatory EHR serving 150K providers bootstrapped to scale; Sunoh.ai ambient clinical documentation and revenue cycle management competing with Epic and athenahealth for practices.
About
eClinicalWorks is one of the largest electronic health record (EHR) and practice management software providers in the United States, serving approximately 150,000 providers across 850,000 care sites with ambulatory EHR, revenue cycle management, patient engagement, and population health tools. Founded in 1999 by Girish Navani and headquartered in Westborough, Massachusetts, eClinicalWorks is privately held and is notable for being a bootstrapped company that has grown to significant scale without venture capital funding, generating substantial annual revenue from its large installed physician base.\n\neClinicalWorks' platform covers the ambulatory (outpatient) clinical workflow: clinical documentation with specialty-specific templates, order entry for labs and imaging, e-prescribing, chronic disease management registries, telehealth (healow TeleVisits), and patient portal. The revenue cycle management capabilities handle insurance claims submission, denial management, and patient billing. Population health tools enable practices and health systems to identify at-risk patient populations and coordinate care across attributed patients.\n\nIn 2025, eClinicalWorks competes with Epic (the dominant health system EHR), athenahealth (cloud-native ambulatory EHR), Oracle Health (Cerner), and Modernizing Medicine for physician practice EHR market share. The company has faced regulatory challenges — in 2017, eClinicalWorks paid $155 million to settle Department of Justice charges related to EHR certification fraud. Despite this, the company retained most of its customer base due to high switching costs inherent in EHR changes. The 2025 strategy focuses on its AI assistant Sunoh.ai (ambient clinical documentation that automatically generates SOAP notes from recorded patient visits), expanding telehealth capabilities, and growing the healow patient engagement platform.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.